ABSTRACT
La telangiectasia esencial progresiva (TEP) es una entidad infrecuente que afecta preferentemente a mujeres de edad media. Clínicamente se caracteriza por el desarrollo progresivo de vasos telangiectásicos que inicialmente aparecen en la región distal de las extremidades inferiores y posteriormente se extienden de forma ascendente hacia el tronco y los miembros superiores. Describimos un nuevo caso de TEP en una mujer de 53 años. Se realiza diagnóstico diferencial con otras entidades caracterizadas por el desarrollo de múltiples telangiectasias (AU)
Progressive essential telangiectasia (PET) is a rare skin disorder that affects mainly middle-age women. It is clinically characterized by the development of telangiectases which first appear on distal lower extremities and progressively spread to the trunk and upper limbs. We report a new case of PET in a 53-year-old woman. Differential diagnosis should be performed with other diseases characterized by the development of multiple telangiectasias (AU)
Subject(s)
Humans , Female , Middle Aged , Hemostatic Disorders/diagnosis , Telangiectasia, Hereditary Hemorrhagic/diagnosis , Diagnosis, Differential , Blood Vessels/physiopathologyABSTRACT
Injection site reactions (ISRs) are the most common adverse effect reported with etanercept therapy. It has been observed that some patients treated with etanercept develop ''recall ISRs'', that are reactions at sites where etanercept was previously injected after the last injection. Etanercept-associated recall ISRs have been scarcely published. We report two patients with rheumatoid arthritis who developed recall ISRs during etanercept therapy. Biopsy specimens from ISRs demonstrated a superficial perivascular lymphocytic infiltrated with a few eosinophils. Immunohistochemical study in both cases revealed that T cells bearing a CD4+ phenotype mostly composed the inflammatory infiltrate. Our observations suggest that ISRs may be mediated by classic cellular-hypersensitivity reactions directed by CD4+ T lymphocytes.
Subject(s)
Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Drug Eruptions/etiology , Immunoglobulin G/adverse effects , CD4-Positive T-Lymphocytes/pathology , Drug Eruptions/immunology , Drug Eruptions/pathology , Edema/chemically induced , Edema/immunology , Edema/pathology , Erythema/chemically induced , Erythema/immunology , Erythema/pathology , Etanercept , Female , Humans , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/pathology , Injections, Subcutaneous/adverse effects , Middle Aged , Receptors, Tumor Necrosis FactorABSTRACT
The case of a patient with hepatitis C virus infection who presented with symmetric ulcers of the legs is reported. She was found to have type III mixed cryoglobulinemia, high titers of anticardiolipin antibodies, lupus anticoagulant, and a free protein S deficiency. To our knowledge, this is the first reported case of such an association. The role of these factors in the pathogenesis of skin lesions in the setting of hepatitis C virus infection is discussed.
ABSTRACT
We report a case of a 38-year-old man showing the yellow nail syndrome in association with minimal change nephrotic syndrome. Treatment with prednisone and vitamin E resulted in complete resolution of the nephrotic syndrome and slow improvement of the yellow nails, respectively. Although the rare yellow nail syndrome has been described in association with renal disease, this is the first report of the association of this syndrome with minimal change nephrotic syndrome.
